Recent studies have suggested that the “inhibition of DREAM complex formation” in certain cancer types may enhance anticancer effects by reactivating quiescent cancer cells, such as through DYRK1A inhibitor treatment [24,25,57,77,88]. Here, KCNIP3 is linked to cancer.